Home Cart Sign in  
Chemical Structure| 112885-42-4 Chemical Structure| 112885-42-4

Structure of Mosapride Citrate
CAS No.: 112885-42-4

Chemical Structure| 112885-42-4

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Mosapride Citrate is both a selective 5HT4 agonist and a 5HT3 antagonist, use as a gastroprokinetic agent.

Synonyms: AS-4370 citrate; TAK-370 citrate; Mosapride (citrate)

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Mosapride Citrate

CAS No. :112885-42-4
Formula : C27H33ClFN3O10
M.W : 614.02
SMILES Code : O=C(NCC1CN(CC2=CC=C(F)C=C2)CCO1)C3=CC(Cl)=C(N)C=C3OCC.O=C(CC(C(O)=O)(O)CC(O)=O)O
Synonyms :
AS-4370 citrate; TAK-370 citrate; Mosapride (citrate)
MDL No. :MFCD01666680
InChI Key :HUZTYZBFZKRPFG-UHFFFAOYSA-N
Pubchem ID :119583

Safety of Mosapride Citrate

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H332-H335
Precautionary Statements:P280-P305+P351+P338-P310

Related Pathways of Mosapride Citrate

GPCR

Isoform Comparison

Biological Activity

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT02982668 Severe Stroke ... More >> Acute Stroke Dysphagia Less << Not Applicable Recruiting December 2022 China, Shaanxi ... More >> Xijing Hospital Recruiting Xi'an, Shaanxi, China, 710032 Contact: Fang Yuan, PhD    +86-29-84771319    yuanfang@fmmu.edu.cn    Principal Investigator: Wen Jiang, PhD          Tangdu Hospital Recruiting Xi'an, Shaanxi, China, 710038 Contact: Peng Guo       1443291624@qq.com    Principal Investigator: Wei Zhang, MD          The First Affiliated Hospital of Xi'an Jiaotong University, Recruiting Xi'an, Shaanxi, China, 710061 Contact: Kang Huo, MD       huokangster@qq.com    Principal Investigator: Kang Huo, MD          Yulin No.2 Hospital Not yet recruiting Yunlin, Shaanxi, China, 719000 Contact: Wenzong Wang, MD       wwz0938@126.com    Principal Investigator: Wenzong Wang, MD Less <<
NCT03600974 - Not yet recruiting July 1, 2021 -
NCT03225248 Functional Dyspepsia Phase 3 Completed - -
NCT01984931 Nausea Vomiti... More >>ng Less << Phase 3 Unknown December 2013 Korea, Republic of ... More >> Chungmu General Hopsital Recruiting Seoul, Yeongdeungpo-gu, Korea, Republic of, 150-034 Contact: Sang Hoon Lhee, MD, Phd    +82 (2) 2068/4525    cmirb@naver.com    Principal Investigator: Paolo Alan B Tabar, MD Less <<
NCT02831543 Functional Dyspepsia Phase 3 Unknown June 2017 Korea, Republic of ... More >> Seoul National University Bundang Hospital Recruiting Seong Nam, Kyung-gi, Korea, Republic of Contact: Nayoung Kim, PhD, MD          Principal Investigator: Nayoung Kim, M.D., Ph.D. Less <<
NCT01274793 Functional Constipation ... More >> Functional Diarrhea Less << Phase 1 Unknown December 2015 China, Hubei ... More >> Institute of Integrated Traditional Chinese and Western Medicine, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology Recruiting Wuhan, Hubei, China, 430030 Contact: Guangying Huang, doctor    86-027-8366-3266    Gyhuang@tjh.tjmu.edu.cn    Principal Investigator: Mingmin Zhang, Doctor          Principal Investigator: Cuihong Zheng, Doctor          Principal Investigator: Fan Xiong, Doctor          Principal Investigator: Ying Wang, Master          Principal Investigator: Man Tian, Master Less <<
NCT01781897 Functional Constipation Phase 1 Unknown December 2015 China, Hubei ... More >> Hospital of Huazhong University of Science and Technology Recruiting Wuhan, Hubei, China, 430000 Contact: Jing Gui, Master    +8615327285070    841946472@qq.com    Principal Investigator: Jing Gui, Master          Hubei Provincial Hospital of TCM Recruiting Wuhan, Hubei, China, 430000 Contact: Feng Hu, Doctor    +8613469974981    351552735@qq.com    Principal Investigator: Feng Hu, Doctor          Institute of Integrated Traditional Chinese and Western Medicine, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology Recruiting Wuhan, Hubei, China, 430030 Contact: Guangying Huang, doctor    86-027-8366-3266    Gyhuang@tjh.tjmu.edu.cn    Principal Investigator: Mingmin Zhang, Doctor          Principal Investigator: Cuihong Zheng, Doctor          Principal Investigator: Xiaohu Xu, Doctor Less <<
NCT03149393 Functional Dyspepsia ... More >> Traditional Chinese Medicine Less << Phase 1 Phase 2 Not yet recruiting December 31, 2019 -
NCT01411501 Constipation Phase 3 Completed - China ... More >> No.5 Beixiange Street, Xuanwu District Beijing, China, 100053 Less <<
NCT02887573 Colorectal Polyps Phase 4 Active, not recruiting July 2017 -
NCT01411501 - Completed - -
NCT03040817 Gastric Peroral Endoscopic Pyl... More >>oromyotomy (G-POEM) Less << Not Applicable Recruiting December 16, 2019 China, Jiangsu ... More >> Zhongda Hospital Southeast University Recruiting Nanjing, Jiangsu, China Contact: Ruihua Shi       ruihuashi@126.com Less <<
NCT01505777 Irritable Bowel Syndrome Witho... More >>ut Diarrhea Less << Phase 2 Completed - Korea, Republic of ... More >> 16 institutions including Gangnam Severance hospital Seoul, Korea, Republic of Less <<
NCT00663897 Functional Dyspepsia ... More >> Epigastric Pain Syndrome Post Prandial Distress Syndrome Less << Phase 4 Completed - Taiwan ... More >> Lotung Poh-Ai hospital Lotung Town, Ilan county, Taiwan, 26546 Less <<
NCT02984930 Gastroesophageal Reflux Diseas... More >>e Less << Not Applicable Unknown July 2018 -
NCT02606617 Type 2 Diabetes Phase 4 Unknown December 2016 -
NCT01094847 Bioequivalence Phase 1 Completed - Korea, Republic of ... More >> Seoul National University Hospital Seoul, Korea, Republic of Less <<
NCT02180334 Diabetes Mellitus, Type 2 Phase 4 Completed - Korea, Republic of ... More >> Seoul National University Hospital Seoul, Korea, Republic of, 110-744 Less <<
NCT00742872 - Terminated(Poor recruitment, h... More >>igh drop out rate) Less << - -
NCT00742872 Constipation-Predominant Irrit... More >>able Bowel Syndrome Less << Phase 3 Terminated(Poor recruitment, h... More >>igh drop out rate) Less << - Lebanon ... More >> American University of Beirut Medical Center Beirut, Lebanon Less <<
NCT02433847 Constipated Irritable Bowel Sy... More >>ndrome Chronic Constipation Healthy Less << Phase 4 Unknown December 2016 -
NCT03477266 Prevention of Postoperative Il... More >>eus Less << Phase 3 Completed - Egypt ... More >> Ashraf nassif Elmantwe Banha, Elqalopia, Egypt Less <<
NCT02106130 Healthy Phase 1 Completed - Korea, Republic of ... More >> Yonsei University Health System, Severance Hospital Seoul, Korea, Republic of, 120-752 Less <<
NCT01284764 Foreign Body Left During Endos... More >>copic Examination Less << Phase 3 Completed - Korea, Republic of ... More >> Haeundae Paik Hospital, Inje University School of Medicine Busan, Korea, Republic of, 612-030 Less <<
NCT02264587 Diabetic Gastroparesis Phase 4 Unknown December 2015 -
NCT00729339 Gastroesophageal Reflux Diseas... More >>e Less << Phase 4 Completed - Taiwan ... More >> Lotung Poh-Ai Hospital Lotung Town, Ilan County, Taiwan, 265 Less <<
NCT02201316 Gastritis Phase 1 Completed - India ... More >> GSK Investigational Site Hyderabad, India, 500 013 Less <<
NCT02056405 Postoperative Ileus Phase 4 Unknown December 2017 Argentina ... More >> Italian Hospital of Buenos Aires Recruiting Buenos Aires, State Capital, Argentina, 1199 Principal Investigator: Virginia M Cano Busnelli, MD          Sub-Investigator: Natalia L Gomez, MD          Sub-Investigator: Jeremias Goransky Patiño, MD Less <<

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

1.63mL

0.33mL

0.16mL

8.14mL

1.63mL

0.81mL

16.29mL

3.26mL

1.63mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories